Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy

Helicobacter

Volumn 18, Issue 5, 2013, Pages 373-377

  Liao, Jingxian ^a   Zheng, Qing ^a   Liang, Xiao ^a   Zhang, Wei ^a   Sun, Qinjuan ^a   Liu, Wenzhong ^a   Xiao, Shudong ^a   Graham, David Y ^b   Lu, Hong ^a  

^a BEIJING HOSPITAL   (China)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amoxicillin; Bismuth; Eradication therapy; Helicobacter pylori; Levofloxacin

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; LANSOPRAZOLE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ALLERGY; STOMACH PAIN; UREA BREATH TEST;

AMOXICILLIN; BISMUTH; ERADICATION THERAPY; HELICOBACTER PYLORI; LEVOFLOXACIN;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BISMUTH; BREATH TESTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84881587301     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12052     Document Type: Article

References (20)

1. Cheng H, Hu FL, Zhang GX, Shi RH, Du YQ, Li ZS, Han W, Li YQ, Wu QD, Qian KD. Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study]. Zhonghua Yi Xue Za Zhi 2010;90:79-82.
2. Yan X, Zhou L, Song Z, et al. Sequential therapy for Helicobacter pylori eradication in adults compared with triple therapy in China: a multi-center, prospective, randomized, control trial. Helicobacter 2011;16(Suppl. 1):87.
3. Zheng Q, Dai J, Li X, Lu H, Xiao S. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infection; a single- center, randomized, open and parallel-controlled study. Chin J Gastroenterol 2009;14:8-11.
4. Di Caro S, Assunta Zocco M, Cremonini F, Candelli M, Nista EC, Bartolozzi F, Armuzzi A, Cammarota G, Santarelli L, Gasbarrini A. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002;14:1309-12.
5. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003;35:711-5.
6. Malfertheiner P, Megraud F, O'Morain CA; European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-64.
7. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010;16:5118-21.
8. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010;15:460-6.
9. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
10. Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011;16:420-6.
11. Pan X, Li Y, Qiu Y, Tang Q, Qian B, Yao L, Shi R, Zhang G. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. Clin Ther 2010;32:2003-11.
12. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
13. Chuah SK, Tai WC, Hsu PI, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment-a pilot study. Helicobacter 2012;17:374-81.
14. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
15. Graham DY, Shiotani A. Which therapy for Helicobacter pylori infection? Gastroenterology 2012;143:10-2.
16. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am 2010;39:465-80.
17. Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009;41:480-5.
18. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009;14:61-5.
19. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007;51:346-9.
20. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11:441-5.